Your browser doesn't support javascript.
loading
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.
Ladoire, S; Mignot, G; Dalban, C; Chevriaux, A; Arnould, L; Rébé, C; Apetoh, L; Boidot, R; Penault-Llorca, F; Fumoleau, P; Roché, H; Spielmann, M; Levy, C; Lortholary, A; Eichler, F; Mesleard, C; Bonnetain, F; Ghiringhelli, F.
Affiliation
  • Ladoire S; Department of Medical Oncology. Centre Georges-François Leclerc, Dijon; Institut National de la Santé et de la Recherche Médicale, Avenir Team INSERM, CRI-866 University of Burgundy, Dijon.
  • Mignot G; Institut National de la Santé et de la Recherche Médicale, Avenir Team INSERM, CRI-866 University of Burgundy, Dijon.
  • Dalban C; Biostatistics and Epidemiological Unit, EA 4184, Dijon.
  • Chevriaux A; Department of Medical Oncology. Centre Georges-François Leclerc, Dijon; Institut National de la Santé et de la Recherche Médicale, Avenir Team INSERM, CRI-866 University of Burgundy, Dijon.
  • Arnould L; Department of Pathology and Biology of Tumors.
  • Rébé C; Department of Medical Oncology. Centre Georges-François Leclerc, Dijon; Institut National de la Santé et de la Recherche Médicale, Avenir Team INSERM, CRI-866 University of Burgundy, Dijon.
  • Apetoh L; Department of Medical Oncology. Centre Georges-François Leclerc, Dijon; Institut National de la Santé et de la Recherche Médicale, Avenir Team INSERM, CRI-866 University of Burgundy, Dijon.
  • Boidot R; Molecular Genetics Laboratory, Centre Georges François Leclerc, Dijon.
  • Penault-Llorca F; Department of Pathology, Centre Jean Perrin, Clermont Ferrand.
  • Fumoleau P; Department of Medical Oncology. Centre Georges-François Leclerc, Dijon.
  • Roché H; Department of Medical Oncology, Institut Claudius Regaud, Toulouse.
  • Spielmann M; Department of Medicine and Translational Research Unit, Institut Gustave Roussy, Villejuif.
  • Levy C; Department of Medical Oncology, Centre François Baclesse, Caen.
  • Lortholary A; Department of Medical Oncology, Centre Paul Papin, Angers.
  • Eichler F; Department of Medical Oncology; Hopital Civil, Strasbourg.
  • Mesleard C; Comité sein (PACS), UNICANCER, Paris, France.
  • Bonnetain F; Biostatistics and Epidemiological Unit, EA 4184, Dijon.
  • Ghiringhelli F; Department of Medical Oncology. Centre Georges-François Leclerc, Dijon; Institut National de la Santé et de la Recherche Médicale, Avenir Team INSERM, CRI-866 University of Burgundy, Dijon. Electronic address: fghiringhelli@cgfl.fr.
Ann Oncol ; 23(10): 2552-2561, 2012 Oct.
Article in En | MEDLINE | ID: mdl-22431701
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Anthracyclines / Forkhead Transcription Factors / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2012 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Anthracyclines / Forkhead Transcription Factors / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2012 Type: Article